RxDoctor Payments DataLook up a doctor →

Matthew Sherwood, MD

Interventional Cardiology · Falls Church, VANPI 1245356435

Payments from drug & device makers

$511,926in general payments, 2019–2025

Across 491 payments — averaging $1042.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$241K
  • Medtronic$211K
  • Abbott$39K
  • Daiichi Sankyo Inc.$15K
  • Edwards Lifesciences$2K
  • Philips North America LLC$1K
  • plus $3K from 12 others
$6,017in research payments, 2019–2025

Across 10 payments — averaging $601.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$6K
  • Abiomed$142

What the payments were for

  • Consulting fees$34,77518%
  • Speaking & faculty fees$102,87553%
  • Travel & lodging$38,81020%
  • Food & beverage$16,3348%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$511,926 in reported general payments places this provider in the 95th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$213,717
Medicare patients
446
Services billed
980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$46,947
Metoprolol Succinate74$1,643
Rosuvastatin Calcium81$1,572
Atorvastatin Calcium112$1,446
Ezetimibe36$1,018
Valsartan17$756
Carvedilol46$625
Losartan Potassium55$394
Lisinopril48$352
Amlodipine Besylate45$301
ClopidogrelClopidogrel Bisulfate18$299
Spironolactone16$207
Ramipril11$144
Isosorbide Mononitrate ErIsosorbide Mononitrate11$130
FenofibrateFenofibrate Nanocrystallized13$129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$114$46,94737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 176 interventional cardiology providers in Virginia.

Other interventional cardiology in Falls Church

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →